Prediction of Alzheimer’s disease with serum lipid levels in Asian individuals: a meta-analysis

Wu, Yufei; Wang, Zhibin; Jia, Xueping; Zhang, Huan; Zhang, Hong; Li, Junlin; Zhang, Kejin

doi:10.1080/1354750x.2019.1571633

Cited by 23 publications

(28 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This concept refers to abnormal levels of lipids or lipoproteins in the blood, which include high levels of low-density lipoprotein (LDL-C), low levels of high-density lipoprotein (HDL-C), total cholesterol (TC) and triglycerides (TG) [ 1 ]. According to previous results, the overall performance of four independent test results should be considered indexes for the prediction of AD, and provide accurate information on an individual’s lipid metabolism status or serum lipid and cholesterol levels [ 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Background: Alzheimer’s disease (AD) is the most common subtype of dementia. In the last ten years, the relationship between cholesterol and AD has been investigated. Evidence suggests that cholesterol is associated with AD and represents promising targets for intervention. However, the causality of these associations is unclear. Therefore, we sought to conduct a meta-meta-analysis to determine the effect of cholesterol on the development AD. Then, we assessed the effect of serum levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC) and triglycerides (TG), on AD risk. Methods: A systematic search of meta-analyses was conducted. Scopus, Web of Science, Science direct, PubMed and Google academic system databases were reviewed. Results: We found 100 primary studies and five meta-analyses to analyze the relationships between cholesterol and AD. The total effect of cholesterol on risk of AD was significant and heterogeneous. Subgroup analysis shows that LDL-C levels influence the development of AD. However, non-significant effects of HDL-C, TC and TG levels on AD were found. Conclusions: These results strengthen the evidence that LDL-C cholesterol levels increase risk for AD. More initiatives to investigate the relationship between cholesterol and AD are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Other studies share the same finding [ 21 , 22 ]. However, some studies did not find an association between high triglycerides levels and high levels of HDL-Cproteins and AD [ 1 , 12 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nevertheless, there is still no coherent conclusion in this field. The parameters of blood lipid profiles have been recognized as potential biomarkers and have been reported to be associated with the risk of AD, which include total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) (Wu et al, 2019). Lipids including TC and HDL-C are currently used as tools to assess the risk of AD and dementia in midlife (Anstey et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Revealing a Novel Landscape of the Association Between Blood Lipid Levels and Alzheimer's Disease: A Meta-Analysis of a Case-Control Study

Tang

Wang

Yang

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

Objectives: Blood lipid profiles have been ambiguously reported as biomarkers of AD in recent years. This study was conducted to evaluate the correlation between blood lipid levels and AD in later-life and to explore the effectiveness and reliability of blood lipid profiles as biomarkers of AD. Methods: Database searching was conducted using PubMed, the Cochrane Library, EMBASE, and Medline. This study was designed following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) criteria. Review Manager 5.3 (RevMan 5.3) software was adopted to perform meta-analysis evaluating the standard mean difference (SMD) with its 95% confidence intervals (CI). Results: A total of 5,286 participants were enrolled from 27 case-control studies in this meta-analysis. The pooled results demonstrated that total cholesterol (TC) level was significantly associated with AD in late-life (SMD = 0.17, 95% CI: [0.01, 0.32], P = 0.03), especially in the subgroup under 70 years old (SMD: 0.45, 95% CI: [0.11, 0.79], P = 0.01) and the subgroup of Western population (SMD: 0.29, 95% CI: [0.04, 0.53], P = 0.02). In the subgroup under 70 years old, the high-density lipoprotein cholesterol (HDL-C) level (SMD = −0.50, 95% CI: [−0.76, −0.25], P = 0.0001) and the low-density lipoprotein cholesterol (LDL-C) level (SMD = 0.59, 95% CI: [0.02, 1.16], P = 0.04) in the AD group were significantly lower and higher than in the control group, respectively. In the subgroup with a sample size larger than 100 subjects, the LDL-C level was significantly higher in AD patients than in the control elderly group (SMD = 0.31, 95% CI: [0.05, 0.56], P = 0.02). There was no significant association between triglyceride (TG) levels and AD in later-life (SMD = −0.00, 95% CI: [−0.12, 0.12], P = 1.00). Tang et al. Association Between Lipids and AD Conclusion: TC can be a new predictive biomarker of AD or cognitive decline in later-life. Increased TC levels are found to be associated with an elevated risk of AD. Decreased HDL-C levels and increased LDL-C levels may relate to an elevated risk of AD in subjects aged 60-70. Further comprehensive researches will be necessary in the future.

show abstract

“…Blood samples from patients from Asia were used for the analysis. 40 LDL is a low-density lipoprotein that consists of proteins and lipids including cholesterol, phospholipids and triglycerides. 41 Increased levels of LDL-C and TC may affect the metabolism of amyloid precursor protein in neurons, and consequently the deposition of amyloid plaques is intensified, leading to the development of AD.…”

Section: Blood Biomarkersmentioning

confidence: 99%

“…Performing a lipid profile as a biomarker in the diagnosis of Alzheimer's disease may be of great benefit, considering imbalance in cholesterol homeostasis as predictive factor. 40 BACE1-AS, a long non-coding RNA, is an antisense BACE1 transcript that significantly influences BACE1 mRNA expression, affirming the formation of Aβ. 42 S.N.…”

Section: Blood Biomarkersmentioning

confidence: 99%

The meaning of blood and cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease

Szarpak

Weronika

Gąbka

et al. 2020

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose: Alzheimer's disease (AD) belongs to the group of neurodegenerative diseases and is the leading cause of dementia worldwide. Its development includes the impact of genetic, metabolic and environmental factors. Despite high prevalence of Alzheimer’s disease and dynamic development of medical science, there is currently no clinically proven causal treatment. The proposed therapies are only symptomatic. However, there is a wide set of substances known as biomarkers that are detected in the blood or in the cerebrospinal fluid (CSF) in the stages preceding full-blown Alzheimer's disease.Brief description of the state of knowledge: In order to obtain material for CSF examination, a lumbar puncture must be performed. It is an invasive procedure, with the risk of complications such as bleeding into the spinal cord, infection or even nerve damage. Obtaining a blood sample for testing specific indicators is less invasive and more widely available. Currently, the diagnostic significance of commonly known markers arising in the progress of the AD pathological process, such as amyloid β, tau protein and its phosphorylated form or β-secretase, is being investigated. As the knowledge on the pathogenesis of AD grows, further markers such as ubiquitin, micro RNA or plasma neurofilament light are tested.Conclusions: There is a collection of biomarkers that can perform a diagnostic function for Alzheimer's disease. Due to the advantages of blood and plasma testing, basing the diagnosis of early forms of AD on these tests seems to be particularly interesting. However, the use of biomarkers on a global scale requires further research and test standardization, as well as the development of guidelines for their interpretation.

show abstract

Prediction of Alzheimer’s disease with serum lipid levels in Asian individuals: a meta-analysis

Cited by 23 publications

References 57 publications

Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis

Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis

Revealing a Novel Landscape of the Association Between Blood Lipid Levels and Alzheimer's Disease: A Meta-Analysis of a Case-Control Study

The meaning of blood and cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease

Contact Info

Product

Resources

About